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ApoptosisMicroRNAs (miRNAs) play a signiﬁcant role in tumor development. Recent studies indicate that
miRNAs are implicated in prostate cancer (PCa). In this study, we found that miR-19a expression
was signiﬁcantly increased in castration-resistant prostate cancer (CRPC) tissues compared with
androgen-dependent prostate cancer (ADPC) tissues. We found that inhibiting the overexpression
of miR-19a in CRPC cells suppressed proliferation and increased apoptosis. Additionally, we found
that miR-19a repressed BTG1 expression by binding to its 30-untranslated region. The overexpres-
sion of BTG1 in CRPC cells signiﬁcantly suppressed proliferation and increased apoptosis. We con-
clude that miR-19a regulates proliferation and apoptosis of CRPC cells by directly targeting the
tumor suppressor gene BTG1.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Prostate cancer (PCa) is the most frequently diagnosed malig-
nancy and the second leading cause of cancer-related deaths in
the USA [1]. The major problem in PCa is the development and
acquisition of castration-resistant prostate cancer (CRPC) pheno-
type, eventually leading to skeletal metastasis, at which no effec-
tive treatments are available [2].
The roles of MicroRNAs (miRNAs) in cellular growth, differenti-
ation, and apoptosis of cancer cells through their interactions with
target mRNAs have been reported in the literature [3].
Accumulated studies have revealed that miRNAs may be oncogenic
or tumor suppressor, in which oncogenic miRNAs can be upregu-
lated, whereas tumor suppressors can be downregulated in cancers
[4]. Previous studies have demonstrated that the expression level
of miR-19a signiﬁcantly increases in prostate cancer cells [5–7].
However, the role of miR-19a in prostate cancer cells remainsunknown. In the present study, we detected the expression of
miR-19a in human androgen-dependent prostate cancer (ADPC)
and CRPC in both cell lines and tissues, and found that miR-19a
was overexpressed in CRPC samples. This ﬁnding indicates that
miR-19a might be oncogenic in CRPC and have diagnostic potential
in CRPC. Furthermore, the anti-proliferative gene BTG1 was
demonstrated to be a direct target of miR-19a. Thus, we aimed at
exploring the relationship between miR-19a and tumor growth,
and their potential mechanisms. In our study, we conclude that
miR-19a is overexpressed in CRPC and that the tumor suppressor
gene BTG1 is a novel target of miR-19a. This ﬁnding show that
miR-19a could have potential implications for therapeutic
approaches to CRPC.
2. Materials and methods
2.1. Tissues
Ten patients were diagnosed with CRPC, since their serum
prostate-speciﬁc antigen (PSA) levels continued to increase during
androgen-deprivation therapy. They all in stage IV and had a
Gleason score >8. They underwent transurethral prostatic resection
because of urinary retention. ADPC tissues were obtained from ten
patients that underwent radical prostatectomy and had never
received any prior treatment. Eight patients were diagnosed with
1486 K. Lu et al. / FEBS Letters 589 (2015) 1485–1490ADPC stage II and two patients with stage III. Seven patients had
Gleason score <7, two patients with Gleason score = 7, and one
patient with Gleason score >7. Disease stage was determined by
pathologic ﬁndings, magnetic resonance image and radio-
nucleotide bone scans according to the 2002 TNM classiﬁcation of
prostate carcinoma. Each specimen was conﬁrmed after PSA stain-
ing. Only those tissues with >60% tumor content were included in
this study. All of the samples were obtained with the patients’
informed consent and with approval from the Ethics Committee of
the Afﬁliated Zhongda Hospital of Southeast University.
2.2. Cell culture and transfection
The human CRPC cell lines (PC3 and Du145) and ADPC cell line
(LNCaP) were maintained in Dulbecco’s modiﬁed Eagle’s medium
supplemented with 10% fetal bovine serum (Gibco) at 37 C in a
humidiﬁed chamber supplemented with 5% CO2. For transfection,
miR-19a inhibitor (50-UCAGUUUUGCAUAGAUUUGCACA-30) and
NC inhibitor (50-CAGUACUUUUGUGUAGUACAA-30) were designed
and chemically synthesised by Genepharma (Shanghai, China).
Cell transfection was performed using Lipofectamine 2000
Reagent (Invitrogen), according to the manufacturer’s protocol.
The transfection efﬁciency of miR-19a inhibitor was greater than
80% in both cell lines, which was monitored by using
FAM-labeled oligonucleotide.
2.3. RNA isolation and quantitative real-time PCR
Following RNA extraction [8], the miRNA fraction was con-
verted into cDNA using TaqMan MicroRNA Assay according the
manufacturer’s protocol (Applied Biosystems) [9]. The following
PCR conditions were used to amplify each miRNA: 95 C for
3 min, 40 cycles of 95 C for 30 s, 56 C for 30 s, and 72 C for
30 s. Real-time PCR reactions were run in a 7300 Real-time PCR
System (Applied Biosystems). The expression of U6 was used as a
control. The relative expression of miRNA was calculated using
2DDCt method.
2.4. Western blot
The proteins were resolved on 12.3% sodium dodecyl sulfate–
polyacrylamide gels and then transferred electrophoretically onto
a polyvinylidene ﬂuoride membrane. Blots were blocked with 5%
skim milk at room temperature (25 C) for 2 h, followed by incuba-
tion with speciﬁc antibodies for BTG1 (1:500, Santa), Cyclin D1
(1:500, Santa), Cyclin B1 (1:500, Santa), or GAPDH (1:3000, Cell
Signaling Technology) at 4 C overnight. The membranes were
washed and incubated with goat anti-rabbit secondary antibody
(1:4000, Zhongshan Golden Bridge Biotechnology) at room tem-
perature for 1 h and speciﬁc protein bands were detected using
enhanced chemiluminescence.
2.5. MTT assay
The MTT assay is based on the protocol ﬁrst described by
Mossman [10]. Brieﬂy, DU145 and PC3 cells with miR-19a inhibitor
or NC inhibitor and BTG1 or pCI-neo plasmid and siBTG1 or NC
transfected for >24 h were added on 96-well plates (3000 cells
per well). The plates were then incubated at 37 C in a humidiﬁed
atmosphere containing 5% CO2 for 24, 48, and 72 h. Wells contain-
ing only a complete medium were used as blank controls. Up to
20 ll of MTT (5 mg/ml) was added to each well, and the plates
were incubated at 37 C for another 4 h. The plates were spun at
1000 rpm for 3 min, and DMSO was added to each well to dissolve
the formazan and absorbance was read at 490 nm using an auto-
matic multi-well spectrophotometer (Bio-Rad).2.6. Cell cycle and apoptosis analysis
Cell cycle and apoptosis distributions were analyzed using FACS
ﬂow cytometer (Becton-Dickson Bioscience). Cells were trans-
fected with miR-19a inhibitor or NC inhibitor and BTG1 or
pCI-neo plasmid and siBTG1 or NC in 6-well plates for 72 h and
then submitted for FACS analysis. After centrifugation, cells were
ﬁxed in 75% ice-cold ethanol at 20 C overnight. Subsequently,
cells were stained with 50 lg/ml of propidium iodide (PI) and
1 mg/ml of RNase for 30 min, and analyzed by ﬂow cytometer at
542 nm. The results were processed with ModFit software. To
detect phosphatidylserine externalization as an endpoint indicator
of early apoptosis, ﬂow cytometry was performed using PI and
annexin V-FITC according to the manufacturer’s instructions.
2.7. Rescue experiment
Rescue experiment was performed by cotransfection with
miR-19a inhibitor and BTG1-siRNA (50-UUGUUGGGUCUCACACUC
AA-30) and NC (50-CAACCCAGAGUGUGAGUUCUU-30) in Du145 cells
and PC3 cells using lipofectamine 2000 as described above.
2.8. Animal model and tumor-formation assay
BALB/C nu/nu male mice (6 weeks) were purchased from
Shanghai SLAC Laboratory Animals. All animal experiments were
conducted according to the National Institute of Health Guide for
the Care and Use of Laboratory Animals and were approved by
the ethics committee of the Afﬁliated Zhongda Hospital of
Southeast University. Du145 cells were transfected with miR-19a
inhibitor or NC inhibitor for 48 h. Cells were collected, resuspended
at a concentration of 2  107 cells/ml of Matrigel (BD) and inocu-
lated into nude mice subcutaneously on both ﬂanks with 0.1 ml
cells (total 2  106 cells), after alcohol preparation of the skin.
Tumor volume was calculated each week using the formula:
(length width2)/2. Four weeks later, all tumors were collected
to measure their volumes. Tumors were formalin ﬁxed immedi-
ately, following excision and parafﬁn embedded.
2.9. Immunohistochemical staining (IHC)
The parafﬁn embedded xenograft tumors were stained with
antibody against Ki-67 and CD34 (both 1:100, Abcam) according
to the manufacturer’s instructions, followed by microscopic
visualization.
2.10. Plasmid construction and transfection
BTG1 was ampliﬁed using the following primer sequences:
sense, 50-GGAATTC ATGCATCCCTTCTACACCCGG-30; antisense, 50-
CGACGCGTTTAACCTGATACAGTCATCAT-30. Template cDNA was
obtained from PC3 cells. PCR products were ligated into a
pCI-neo vector between EcoRI and Mlu1 sites.
2.11. Luciferase assays
The 30-UTR segment of BTG1 mRNA with miR-19a binding site
was ampliﬁed by PCR fromDU145 DNA.Wild-type ormutant forms
of BTG1 mRNA 30UTR were ampliﬁed by PCR from a DU145 cDNA
library, digested by MluI and HidIII, and cloned into the MluI and
HidIII restriction sites downstream of the open reading frame of
luciferase in pMIR-reporter Vector (Ambion) to generate the
BTG-30-UTR reporter. The PCR primers were as follows:
BTG1-30UTR-sense 50-TCGACGCGT GCAGTAAATCTCGCAGG-30;
BTG1-30UTR-antisense, 50-TCCCAAGCTTATTCTGGTCACTTGCTACTT
T-30; BTG1-30UTR mut-sense, 50-TCG ACGCGTGAACGCACTAT
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AAGCTTACAAGGTCTGACCATTTCCC-30 For reporter assays, Du145
and PC3 cells were transfected with BTG1-30UTR or mutated
BTG1-30UTR reporter plasmid andmiR-19a inhibitor or NC inhibitor
mimics. The cells were lysed at 48 h post-transfection, and the pro-
teins were isolated. Luciferase activities were measured by dualFig. 1. (A and B) The expression of miR-19a was signiﬁcantly up-regulated in CRPC
than ADPC in both cell lines and tissues. ***P < 0.001.
Fig. 2. BTG1 is a direct target of miR-19a in CRPC cells. (A) The genome microarray data
tissues. (B) BTG1, Cyclin D1 and Cyclin B1 protein levels were measured when treated w
luciferase reporter cloning site in the pMIR-reporter dual luciferase vector. With decrea
rescued the repressive effect of miR-19a inhibitor in both Du145 and PC3 cells. *P < 0.05luciferase assays (Promega) and normalized against the activity of
the Renilla luciferase gene.
2.12. Statistic analysis
All statistical analyses were conducted using SPSS software
version 16.0 (SPSS, Inc.). All experiments were repeated thrice.
Statistical analyses utilized a two-tailed Student’s t-test.
Statistical signiﬁcance was set as P < 0.05.3. Results
3.1. MiR-19a expression is higher in CRPC tissues than in ADPC tissues
Some recent reports have shown that miR-19a expression was
signiﬁcantly higher in CRPC cells than in ADPC cells [5–7,11]. To ver-
ify this ﬁnding, we ﬁrstly detected the basic expression level of
miR-19a in LNCaP, Du145 and PC3 cell lines, and we also detected
the expression of miR-19a in 10 ADPC tissues and 10 CRPC tissues
by qRT-PCR. The expression of miR-19a was signiﬁcantly
up-regulated in CRPC than ADPC in both cell lines and tissuesfrom the GSE35988 database about BTG1 was analyzed in ADPC tissues and CRPC
ith miR-19a inhibitor in Western blotting analysis. (C) BTG1 30-UTR was cloned into
sed miR-19a level, luciferase activities increased. (D–G) Down-expression of BTG1
.
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ulation of pathways responsible for ADPC-to-CRPC transformation.
3.2. BTG1 as direct target of miR-19a
We used the miRNA target prediction programs PicTar and
TargetScan to perform bioinformation analysis to identify potential
targets of miR-19a. Among these targets, BTG1 was found to have a
putative binding site within its 30UTR for miR-19a. Besides, we
analyzed the genomemicroarray data from the GSE35988 database
(Fig. 2A) [12], and found that BTG1 was low regulation in CRPC tis-
sues than ADPC tissues, which was indicated that BTG1 might be a
target of miR-19a in PCa. We performed Western blot for BTG1,
Cyclin B1, and Cyclin D1 expression in CRPC cells with either
miR-19a inhibitor or NC inhibitor transfected. Interestingly,
miR-19a inhibitor signiﬁcantly increased the expression of BTG1
and decreased the expression of Cyclin B1 and Cyclin D1
(Fig. 2B). Consequently, luciferase reporter assay was performed
to conﬁrm whether miR-19a could directly target to BTG1 30UTR.
As expected, the luciferase assay clearly showed that miR-19a inhi-
bitor increased luciferin oxidation and light development com-
pared with NC inhibitor. Moreover, the mutated BTG1-30UTR was
not affected by miR-19a inhibitor, thus strongly strengthening that
BTG1 was a direct target of miR-19a (Fig. 2C). To ascertain that the
miR-19a regulates the proliferation and apoptosis of CRPC cells
through its interaction with BTG1, a rescue experiment was also
performed. We inhibited BTG1 expression using a small interferingFig. 3. (A) Transfection with miR-19a inhibitor or BTG1 inhibited cell growth compared
prostate cancer cells transfected with miR-19a inhibitor or BTG1. (C) Both miR-19a inhiRNA and measured the effect of BTG1 knockdown on Du145 and
PC3 cells. The results indicated that knock down of BTG1 increased
cells proliferation and suppressed their apoptosis, the effects of
which are similar to rescue the repressive effects of miR-19a inhi-
bitor on CRPC cells (Fig. 2D–G).
3.3. Both miR-19a inhibitor and BTG1 regulate the proliferation and
apoptosis of CRPC cells
To investigate the effect of miR-19a and BTG1 in CRPC, we
transfected miR-19a inhibitor or BTG1 plasmid to inhibit the
mature miR-19a levels or enhance the mature BTG1 levels in two
CRPC cell lines, namely, PC3 and Du145. MTT assay demonstrated
that miR-19a inhibitor or BTG1 signiﬁcantly inhibited the growth
of PC3 and Du145 cells within 48 and 72 h (Fig. 3A). The proportion
of G1 phase increased in cells transfected with miR-19a inhibitor
or BTG1 (Fig. 3B), thereby conﬁrming that G1 phase was arrested
by inhibiting miR-19a or enhancing BTG1 in CRPC cells.
Transfection with miR-19a inhibitor or BTG1 in CRPC cells also
increased the proportion of early apoptosis (Fig. 3C). All these
results indicate that miR-19a inhibitor and BTG1 reduce prolifera-
tion and promote apoptosis of CRPC cells.
3.4. MiR-19a inhibitor suppresses tumor growth in vivo
To test the in vivo relationships between miR-19a and prolifer-
ation, miR-19a inhibitor and NC inhibitor in DU145 cells werewith NC inhibitor or pci-neo. (B) The proportion of G1 phase was up-regulated in
bitor and BTG1 increased had a higher rate of apoptosis. *P < 0.05.
Fig. 4. MiR-19a inhibitor suppresses tumor formation in vivo. (A) The tumor volume of the miR-19a inhibitor group was signiﬁcantly reduced compared to that of NC-i group.
(B) MiR-19a inhibitor reduced CD34 and Ki-67 immunostaining in tumors. (C) The BTG1 expression levels in the tumor tissues were measured by using Western blot.
*P < 0.05.
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miR-19a inhibitor inhibited tumor formation of DU145 cells in vol-
ume (Fig. 4A). Moreover, we also performed immunohistochem-
istry to detect the expression of Ki67 and CD34 in tumor tissues.
As shown in Fig. 4B, miR-19a inhibitor also reduced the protein
levels of Ki-67 and CD34 in miR-19a inhibitor-transfected cell tis-
sues. These data suggested that miR-19a inhibitor reduced tumori-
genicity and angiogenesis in the nude mouse xenograft model.
Besides, we also detected the BTG1 expression in the tumor tissues
by using Western blot (Fig. 4C), and found miR-19a inhibitor group
induced high-expression of BTG1, which might indicated that the
miR-19 inhibitor was still functional.
4. Discussion
MiR-19a (has-miR-19a-3p) is located in miR-17-92 cluster,
which also encodes ﬁve other mature miRNAs, miR17, miR-18a,
miR-19b and miR-20a and miR-92a [13]. The miR-17-92 cluster
is identiﬁed as oncomiR, since its encoded miRNAs are
over-expressed in lymphomas and several solid tumors, including
breast [14], lung [15], pancreatic [16] and gastric cancers [17].
MiR-19 was found to be a key oncogenic component of this cluster
[18]. MiR-19a could accelerate tumorigenesis by targeting several
tumor suppressors, such as PTEN [19], MXD1 [20] and CUL5 [21].
Moreover, Qin has shown that microRNA-19a mediated the sup-
pressive effect of laminar ﬂow on cyclin D1 expression in human
umbilical vein endothelial cells [22].
Consistent with previous reports on miR-19a in prostate can-
cers [5–7], we showed that miR-19a upregulation was common
in CRPC tissues and further explored the roles of miR-19a in
CRPC. Our previous study conﬁrmed that the expression of
miR-19a was signiﬁcantly increased in CRPC, so in the following
study, we chose to inhibit the expression of miR-19a to verify its
effects on functional analyses and mechanistic studies [20,21].
In our work, we observed that inhibiting the expression of
miR-19a led to upregulation of BTG1 proteins in the prostate can-
cer cell system. MiR-19a inhibitor also inhibited the expression of
Cyclin B1 and Cyclin D1, which were crucial genes in the cell cycle.
However, Qin reported that the overexpression of miR-19a sup-
pressed the expression of Cyclin D1 in human umbilical vein
endothelial cells. It is possible that the targeted genes of miRNAs
are involved in distinct pathways so that the targeted gene mayhave opposing expression in different cells. Finally, the luciferase
reporter assay and the rescue assay results showed that miR-19a
directly targeted the 30UTR of BTG1 as predicted by bioinformatic
analysis.
Moreover, consistent with the ﬁndings in CRPC, our functional
study indicated that the inhibited expression of miR-19a in
DU145 and PC3 cells not only signiﬁcantly suppressed proliferation
and enhanced apoptosis of CRPC cells in vitro, but also reduced
tumorigenicity and angiogenesis in a nude mouse model in vivo.
BTG1 was recognized as a tumor suppressor gene, and was a
important member of the BTG/TOB family of anti-proliferative
genes [23]. Xin reported that over-expression of BTG1 in human
renal carcinoma cells promoted a G1 arrest [24]. Up-regulation of
BTG1 caused higher percentage of the G0/G1 phases and higher
cell apoptosis in breast cancer cells by regulating CyclinD1, Bcl-2,
and MMP-9 protein expression [25]. In our study, we also con-
ﬁrmed that forced expression of BTG1 that suppressed prolifera-
tion and enhanced apoptosis of CRPC cells in vitro [26].
Our ﬁndings revealed that miR-19a was an oncogene, and BTG1
was a tumor suppressor in prostate cancer. Notably, miR-19a reg-
ulated CRPC cell proliferation and apoptosis by targeting BTG1.
In summary, our study suggests that down-regulation of
miR-19a is signiﬁcantly inhibited the proliferation and enhanced
apoptosis of CRPC cells. MiR-19a plays an important role in CRPC
cells through directly targeting of BTG1. These ﬁndings might pro-
vide a new viewpoint for the mechanism of ADPC-to-CRPC
transformation.
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